University of Michigan Appoints New Dean of School of Public Health

 

University of Michigan pic

University of Michigan
Image: umich.edu

With more than 20 years of experience in the recruiting industry, Scott Robarge is the founder of Another8 in San Francisco. He typically recruits for Tier-1 venture capital companies looking for sales, product, engineering, and operations professionals. Additionally, Scott Robarge holds a bachelor’s in industrial and operations engineering from the University of Michigan (UM).

Recently, UM announced the appointment of a new dean of the School of Public Health, F. DuBois Bowman. Experienced with research in mental health disease and neurological disorders, including depression and Alzheimer’s disease, F. DuBois Bowman holds a master’s in biostatistics from UM and a PhD in biostatistics from the University of North Carolina at Chapel Hill. Effective October 15, he will start a five-year term not only as dean of the School of Public Health but also as a professor of biostatistics, with tenure.

Bowman comes to UM having served as chair of Columbia University’s Mailman School of Public Health and as the Cynthia and Robert Citrone-Roslyn and Leslie Goldstein Professor of Biostatistics. He stated that he is honored to join UM’s renowned School of Public Health, where students and faculty work to promote change through scientific evidence that informs future healthcare policy and community engagement.

Advertisements

Alzheimer’s Association Publishes Risk Guidelines

 

Alzheimer’s Association pic

Alzheimer’s Association
Image: alz.org

As founder of the recruiting firm Another8, Scott Robarge helps early to mid-stage high-tech companies to find skilled talent. Scott Robarge also stands out as an active supporter of the Alzheimer’s Association.

According to a recently published study in Alzheimer’s and Dementia: The Journal of the Alzheimer’s Association, a person’s lifetime risk of developing Alzheimer’s disease depends largely on age, gender, and the presents of dementia symptoms. The researchers have developed a rubric that is unique in its incorporation of changes that occur in the brain as many as 20 years before clinical symptoms appear.

Many people whose brains undergo these changes never develop clinical Alzheimer’s disease, largely because of the prolonged period of pre-clinical asymptomatic presentation. Study author Ron Brookmeyer, PhD, offered the example of a 90-year-old female and 65-year-old female, both with the biomarker of amyloid plaques. Because the 90-year-old has a shorter life expectancy by the time she has reached the age of 90, she would have a lifetime risk that is nearly 21 percent less than that of the 65-year-old.

To evaluate risk, the team’s metric requires information about the patient’s age and whether or not any amyloid deposits are present. The screening also requires assessment of a patient’s level of neuro-degeneration and whether any mild cognitive impairment is present. The presence of all three factors indicates the highest risk.

The chief science officer of the Alzheimer’s Association Dr. Maria Carillo states that risk predictors may prove useful once viable treatments are available. Such risk evaluations also may help to secure volunteers for clinical trials, as a patient may be more likely to volunteer if he or she has a higher risk of developing the disease.

Alzheimer’s Association BOLD Infrastructure Act

BOLD Infrastructure Act pic

BOLD Infrastructure Act
Image: alzimpact.org

Scott Robarge, a recruiting consultant for Bay Area tech companies and the founder of consultancy Another8, supports the Alzheimer’s Association. Thanks to the support of people like Scott Robarge, the Association combats all forms of Alzheimer’s through fundraising, research, and advocacy.

The Alzheimer’s Association and Alzheimer’s Impact Movement have helped to develop the Building Our Largest Dementia (BOLD) Infrastructure for Alzheimer’s Act, a bill which would enhance the quality of medical care for Alzheimer’s patients nationwide. By improving early detection and diagnosis as well as reducing risk and preventing hospitalizations.

The Act would establish Alzheimer’s Centers of Excellence to provide education for healthcare professionals and other stakeholders about brain health. These centers would also expand existing public-private partnerships active in the field of cognitive impairment, provide assistance to public health departments in dealing with Alzheimer’s, and support caregivers. Public health departments would also receive funding specifically targeted at degenerative brain diseases.

Bill Gates Lends Support to Finding a Cure for Alzheimer’s

 

Alzheimer’s Association pic

Alzheimer’s Association
Image: alz.org

An experienced talent recruiter for companies in the technology sector, Scott Robarge previously worked for SlideRocket and Greylock Partners and, since 2010, has presided over the recruiting firm Another8. Beyond his recruiting endeavors, Scott Robarge is a regular supporter of the Alzheimer’s Association.

Alzheimer’s is a cognitive disease that affects more than 5 million Americans and accounted for health care costs of $259 billion in 2017 alone. By 2050, health care costs toward the disease are projected to rise to more than $1 trillion, but the cause to find a cure recently received support from a powerful ally in Bill Gates. The Microsoft cofounder wrote a blog post in November titled “Why I’m Digging Deeper into Alzheimer’s,” in which he notes the importance of finding a cure as people are living longer and, as such, at greater risk to developing the disease.

Most importantly, Gates announced a pair of donations totaling $100 million to support organizations in their efforts to eradicate Alzheimer’s. He is investing $50 million of his personal money in the Dementia Discovery Fund as well as another $50 million in early-phase companies working on “less mainstream” approaches to fighting Alzheimer’s. The billionaire added he is optimistic that a cure can be found, even if it might take more than a decade.

Alzheimer’s Association Funds Gender-Based Research Efforts

Alzheimer’s Association pic

Alzheimer’s Association
Image: alz.org

Scott Robarge is an experienced recruitment professional with more than a decade of experience in the industry. In 2010, he founded Another8, a recruiting firm that specializes in partnering with early to mid-stage technology companies. Outside of his professional pursuits, Scott Robarge focuses his philanthropic efforts toward supporting the Alzheimer’s Association.

The Alzheimer’s Association recently announced $2.2 million in funding for its Sex and Gender in Alzheimer’s (SAGA) initiative that will be distributed to nine studies aimed at understanding why women are disproportionately affected by Alzheimer’s disease.

There are approximately 5 million Americans that suffer from Alzheimer’s, with more than two-thirds of that number being women. According to recent data gathered by the Alzheimer’s Association, in adults over the age of 71, there is a 16 percent rate of the disease, but only an 11 percent rate among men.

While there are some working theories as to why women suffer more than men from Alzheimer’s, researchers still have no definitive answers. The Alzheimer’s Association hopes that, through funding research projects, more knowledge about the gender disparity will be gained.

Antibodies New Wave of Alzheimer’s Research

Alzheimer's Research pic

Alzheimer’s Research
Image: sciencedaily.com

A seasoned recruiter and entrepreneur, Scott Robarge is the founder of Another8, a recruiting firm that primarily acquires talent for fast-paced technology companies. When he isn’t serving as a recruiter, Scott Robarge supports organizations that help lead the fight against Alzheimer’s disease.

Recent research efforts into the treatment of Alzheimer’s disease are focused on fighting the plaques that develop in the brain. Researchers believe that by understanding how to better manage these plaques, they may be able to delay its onset.

These plaques, which are a common sign of the condition, are tiny batches of beta-amyloid protein that deposit themselves in the brain and are responsible for brain cell degradation. Some antibodies, such as Aducanumab, have shown the propensity to reduce the amount of plaques that develop in Alzheimer’s patients, effectively slowing the rate of cognitive decline. It is thought that future research efforts in the battle against Alzheimer’s could include other combinations of medications in conjunction with these sorts of antibodies.

Alzheimer’s Association Uncovers a New Way to Fight Mental Decline

Alzheimer’s Association pic

Alzheimer’s Association
Image: alz.org

Recruiter Scott Robarge possesses decades of experience finding and attracting top talent within the technology sector. He founded Another8 in 2010, and continues to lead the growing talent acquisition firm. Alongside his professional endeavors, Scott Robarge supports the efforts of community and health organizations including the Alzheimer’s Association.

New research presented at the recent Alzheimer’s Association International Conference suggests an unconventional way to improve mental resilience and stave off Alzheimer’s. Scientists have found that individuals who do complex work with the public as part of their job are less likely to experience cognitive decline as they age.

Some people experience white matter hyperintensities (WMHs), which are diseased white spots that show up on brain scans. These contribute to mental decline, and are commonly found in people with Alzheimer’s and similar conditions. However, some people develop WMHs, but never manifest symptoms of mental decline. According to researchers, these people are disproportionately likely to work in mentoring, counseling, or similar fields where complex social engagement is key. Diet seems to be a compounding variable, and more research is needed to make use of this interesting development.